Shenzhen Kexing Pharma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 


12345678910111213...2223»
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, Focus V (anlotinib) / Advenchen, Sino Biopharm
    Eribulin plus anlotinib in advanced soft tissue sarcoma (ERAS): Updates on efficacy and biomarkers. (S100a) -  Apr 23, 2025 - Abstract #ASCO2025ASCO_2024;    
    P2
    Clinical Trial Registration Number: ChiCTR2000038832 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT Clinical Trial Registration Number: ChiCTR2300067650 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT
  • ||||||||||  Ontruzant (trastuzumab-dttb) / Samsung, AffaMed Therap, Mundipharma, Organon, Halaven (eribulin mesylate) / Eisai
    Trial completion date, Trial primary completion date:  ESPERO: Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer (clinicaltrials.gov) -  Apr 17, 2025   
    P2,  N=180, Recruiting, 
    Clinical Trial Registration Number: ChiCTR2300067650 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Feb 2024 --> Dec 2026
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, vinorelbine tartrate / Generic mfg., paclitaxel / Generic mfg.
    Journal:  Selective tubulin-binding drugs induce pericyte phenotype switching and anti-cancer immunity. (Pubmed Central) -  Mar 27, 2025   
    Moreover, a contractile pericyte signature was associated with overall better survival outcome in two independent breast cancer cohorts. This underscores the potential of re-purposing specific anti-cancer drugs to enable synergistic complementation with emerging immunotherapies.
  • ||||||||||  BB-1712 / BlissBio, Halaven (eribulin mesylate) / Eisai
    Preclinical studies of BB-1712: A B7H3-targeting eribulin-containing ADC with the potential to overcome resistance to DNA topoisomerase I inhibitor-containing ADCs (Section 40; Poster Board No: 25) -  Mar 25, 2025 - Abstract #AACR2025AACR_8214;    
    Pharmacokinetic and toxicology assessments in non-human primates revealed a favorable safety profile for BB-1712 at clinically relevant dosages and administration schedules.In summary, our findings suggest that BB-1712 has promising preclinical efficacy and safety profiles as well as the potential to circumvent resistance mechanisms associated with current therapies. These results support the advancement of BB-1712 into clinical trials for patients with B7-H3-expressing solid tumors.
  • ||||||||||  ZSTK3744 / Zenyaku Holdings
    Aryl hydrocarbon receptor agonist ZSTK3744 overcomes chemotherapy resistance in TNBC (Section 21; Poster Board No: 21) -  Mar 25, 2025 - Abstract #AACR2025AACR_8120;    
    Moreover, ZSTK3744 significantly inhibited tumor growth in xenograft models implanted with adriamycin-resistant MDA-MB-468 cells, showing a higher potency than eribulin. ZSTK3744 is a promising agent for overcoming chemotherapy-resistance in TNBC.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, BB-1705 / BlissBio
    Preclinical studies of BB-1705: An EGFR-targeting eribulin-containing ADC with an affinity optimized antibody to minimize potential toxicities to normal tissues (Section 36; Poster Board No: 15) -  Mar 25, 2025 - Abstract #AACR2025AACR_6988;    
    When administered repeatedly via a clinically relevant route and schedule, BB-1705 demonstrated a favorable pharmacokinetic profile and safety in cynomolgus monkeys with manageable hematological side effects and minimal skin toxicity observed even at the highest tested dose (12 mg/kg, Q3W x 3).In summary, our preclinical findings suggest that BB-1705 has the potential to optimize the efficacy and safety profile of EGFR-targeting therapies for cancers characterized by medium to high EGFR expression levels. A clinical trial evaluating BB-1705 is currently underway, aiming to assess its therapeutic potential in treatment of EGFR-expressing human cancers including TNBC, NSCLC and head and neck cancers.
  • ||||||||||  SMP-656 / Chengdu Kelingyuan Pharma, Halaven (eribulin mesylate) / Eisai
    Preclinical development of SMP-656: An eribulin-SuperHydraTM linker based ADC (Section 15; Poster Board No: 12) -  Mar 25, 2025 - Abstract #AACR2025AACR_5468;    
    The SuperHydraTM linker enabled SMP-656 to combine superior stability, efficacy, and safety with the ability to overcome DS-8201a resistance. SMP-656 represents the safest and most effective eribulin-based ADC and is currently in Phase I clinical trials, showing promising tolerability and efficacy.
  • ||||||||||  PLB-002 / Primelink Bio
    PLB-002 is a novel Claudin 6 antibody-drug conjugate for ovarian cancer and testicular germ cell cancer (Section 17; Poster Board No: 19) -  Mar 25, 2025 - Abstract #AACR2025AACR_5415;    
    Here, we describe the development and preclinical characterization of a novel ADC called PLB-002, which consists of a highly selective CLDN6 targeting antibody, PLB-002-ab7, conjugated to a FDA-approved microtubule inhibitor, eribulin, via a Primelink Biotherapeutics proprietary enzyme-cleavable linker with an optimized average drug-to-antibody ratio (DAR) of 4.0. These results show that PLB-002 has remarkable antitumor activity and support the clinical development as a therapeutic ADC for the treatment of ovarian cancer and other CLDN6 expressing solid cancer.*, Equal contributions.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, navitoclax (ABT 263) / AbbVie
    Advancing precision oncology: Development and utilization of breast cancer PDX models for in vivo drug discovery (Section 3; Poster Board No: 6) -  Mar 25, 2025 - Abstract #AACR2025AACR_4830;    
    For the ER+/PR+ HCI-044 model, tamoxifen treatment resulted in PD, but eribulin achieved 100% CR, highlighting subtype-specific therapeutic responses...However, by optimizing these models and integrating patient history, researchers are advancing their fidelity and expanding their applications. These models bridge the gap between preclinical research and clinical outcomes, offering new opportunities to accelerate targeted therapy development and improve patient care.
  • ||||||||||  GQ1033 / GeneQuantum Healthcare, GQ1030 / GeneQuantum Healthcare
    Novel EGFR x cMET bispecific ADC GQ1033 and DLL3-ADC GQ1030 demonstrated promising therapeutic efficacy in preclinical studies (Section 16; Poster Board No: 14) -  Mar 25, 2025 - Abstract #AACR2025AACR_2968;    
    Using the platforms, we created a broad ADC library targeting EGFR x cMET and DLL3, combining antibodies with various formats, different linkers, and payloads like MMAE, Eribulin, Exatecan, Lurbinectedin, and TopoIx...In an osimertinib-resistant NSCLC PDX trial, involving ~10 models with diverse EGFR/cMET expression levels, GQ1033 demonstrated robust antitumor activity with an overall ORR of ~70%... GQ1033 and GQ1030, developed through high-throughput screening leveraging our iGDC
  • ||||||||||  Bria-IMT (SV-BR-1-GM) / BriaCell
    Trial completion date, Trial primary completion date:  BRIA-ABC: Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. (clinicaltrials.gov) -  Mar 13, 2025   
    P3,  N=404, Recruiting, 
    In this case report, we describe the case of a highly pretreated patient with HER-2 positive metastatic breast cancer. Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Jan 2026
  • ||||||||||  Preclinical, Review, Journal:  Selinexor in the treatment of liposarcoma: from preclinical evidence to clinical practice. (Pubmed Central) -  Mar 9, 2025   
    P1, P1/2,
    Ongoing studies, such as the SeliSarc trial (NCT04595994) evaluating selinexor in combination with gemcitabine and the NRSTS2021 trial (NCT06239272) evaluating selinexor in paediatric soft tissue sarcoma, aim to further define its role. The results of these studies will be critical in determining whether selinexor can be incorporated into standard sarcoma treatment.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Journal, PARP Biomarker:  Eribulin exerts multitarget antineoplastic activity in glioma cells. (Pubmed Central) -  Mar 9, 2025   
    Eribulin demonstrates potent anti-glioma effects through apoptosis, mitochondrial dysfunction, and cell cycle disruption. These findings support its potential as a therapeutic option for glioblastoma treatment, warranting further investigation into its mechanisms and clinical applicability.
  • ||||||||||  Datroway (datopotamab deruxtecan) / Daiichi Sankyo, AstraZeneca
    Journal:  Datopotamab deruxtecan (Datroway) for advanced breast cancer. (Pubmed Central) -  Feb 27, 2025   
    These findings support its potential as a therapeutic option for glioblastoma treatment, warranting further investigation into its mechanisms and clinical applicability. No abstract available
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Eribulin-induced Pneumotoxicity in a Patient With Metastatic Triple Negative Breast Cancer: A Case Report (Area K, Hall F (North Building, Exhibition Level), Moscone Center; Poster Board # P1284) -  Feb 24, 2025 - Abstract #ATS2025ATS_1495;    
    Recognizing Eribulin-induced pneumonitis can facilitate early intervention by discontinuing Eribulin and prompt treatment with high-dose corticosteroids and, when necessary, mechanical ventilatory support. This report contributes to the limited literature on Eribulin-related pneumotoxicity, providing a valuable reference for clinicians managing advanced TNBC cases.